1. "Gastrointestinal Oncology Service"
Formats
  1. Journal Article (2302)
  2. Meeting Abstract (1841)
  3. Review (139)
  4. Book Section (123)
  5. Editorial (93)
  6. Guidelines (36)
  7. Correspondence (33)
  8. Conference Paper (23)
  9. Miscellaneous (21)
  10. Research Letter (17)
  11. Book Whole (12)
Groups
  1. Gastrointestinal Oncology Service (4640)
  2. Solid Tumor Oncology Division (4640)
  3. Department of Medicine (4638)
  4. Center for Pancreatic Cancer Research (2270)
  5. Surgery (1040)
  6. Survivorship Research (992)

More Groups

People
  1. Leonard Saltz (790)
  2. Eileen O'Reilly (780)
  3. Ghassan Abou-Alfa (568)
  4. Nancy Kemeny (543)
  5. David Kelsen (537)
  6. David Ilson (433)

More People

Years
  1. 2025 (118)
  2. 2024 (307)
  3. 2023 (362)
  4. 2022 (346)
  5. 2021 (345)
  6. 2020 (326)

More Years

Publications
  1. Journal of Clinical Oncology (1276)
  2. Annals of Oncology (320)
  3. Annals of Surgical Oncology (140)
  4. Cancer (127)
  5. Clinical Cancer Research (107)
  6. Cancer Research (94)

More Publications

Publishers
  1. American Society of Clinical Oncology (1355)
  2. Oxford University Press (447)
  3. Elsevier Inc. (404)
  4. Springer (310)
  5. American Association for Cancer Research (279)
  6. Wiley Blackwell (239)

More Publishers

Results (4640)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase III, randomized, double-blind, multicenter, placebo (P)-controlled trial of rilotumumab (R) plus epirubicin, cisplatin and capecitabine (ECX) as first-line therapy in patients (pts) with advanced MET-positive (pos) gastric or gastroesophageal junction (G/GEJ) cancer: RILOMET-1 study
    Meeting Abstract

    Cunningham, D.; Tebbutt, N. C.; Davidenko, I.; Murad, A. M.; Al-Batran, S. E.; Ilson, D. H.; Tjulandin, S.; Gotovkin, E.; Karaszewska, B.; Bondarenko, I.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Platinum-based combination therapy (PCT) and outcomes for patients (pts) with mixed hepatocellular carcinoma and intrahepatic cholangiocarcinoma (mHCC/ICC)
    Meeting Abstract

    Connell, L. C.; Harding, J. J.; Lowery, M. A.; Kemeny, N. E.; Cercek, A.; Abdelgawad, M. I.; O'Reilly, E. M.; Saltz, L.; Abou-Alfa, G. K.
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Determinants of early mortality in 37,568 colon cancer patients participating in 25 clinical trials of the ACCENT database
    Meeting Abstract

    Cheung, W. Y.; Renfro, L. A.; Yothers, G.; Gray, R. G.; Haller, D. G.; Twelves, C.; Andre, T.; Van Cutsem, E.; Saltz, L.; Grothey, A.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Oxaliplatin can be safely infused at a rate of 1mg/m(2)/min
    Meeting Abstract

    Cercek, A.; Park, V.; Yaeger, R. D.; Reidy, D. L.; Kemeny, N. E.; Stadler, Z. K.; Segal, N. H.; Varghese, A. M.; Saltz, L.
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Confirmation of high prevalence of BAP1 inactivation in mesothelioma
    Meeting Abstract

    Cercek, A.; Zauderer, M. G.; Rimner, A.; Rusch, V. W.; Adusumilli, P. S.; Nash, G. M.; Hmeljak, J.; Ladanyi, M.; Krug, L. M.
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Using mutational load in next generation sequencing (NGS) to identify mismatch repair (MMR) deficiency in colorectal cancer (CRC)
    Meeting Abstract

    Battaglin, F.; Stadler, Z. K.; Cercek, A.; Yaeger, R. D.; Segal, N. H.; Varghese, A. M.; Kemeny, N. E.; Weiser, M. R.; Garcia-Aguilar, J.; Shia, J.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • First stage results of a phase II trial of sorafenib plus doxorubicin (SD) in patients (pts) with advanced hepatocellular carcinoma (HCC) who progressed (POD) on sorafenib (S)
    Meeting Abstract

    Abou-Alfa, G. K.; Capanu, M.; Do, R. K. G.; Hollywood, E.; Ly, M.; Chou, J. F.; Lee, J. K.; Connell, L. C.; Wan, P. J.; Bradley, M.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Randomized phase II study of everolimus (E), leuprolide + letrozole (LL), and E + LL (ELL) in patients (pts) with unresectable fibrolamellar carcinoma (FLC)
    Meeting Abstract

    Abou-Alfa, G. K.; Mayer, R. J.; Cosgrove, D.; Capanu, M.; Choti, M. A.; Atreya, C. E.; Ang, C.; Kelley, R. K.; Do, R. K. G.; Gordan, J. D.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Locoregional therapy for hepatocellular carcinoma with and without extrahepatic spread
    Journal Article

    Leal, J. N.; Gonen, M.; Covey, A. M.; Erinjeri, J. P.; Getrajdman, G.; Sofocleous, C. T.; D'Angelica, M.; DeMatteo, R. P.; Abou-Alfa, G. K.; Jarnagin, W. R.; more...
    Journal of Vascular and Interventional Radiology (2015)

    Fulltext@MSK | Save
  • Novel therapeutics for pancreatic adenocarcinoma
    Journal Article

    Lowery, M. A.; O'Reilly, E. M.
    Hematology/Oncology Clinics of North America (2015)

    Fulltext@MSK | Save